Teijin turns to Pulmagen to plug respiratory pipeline gap
This article was originally published in Scrip
Executive Summary
The pharmaceutical division of Teijin has acquired rights in Japan to Pulmagen Therapeutics' lead CRTh2 antagonist ADC3680, which it will develop initially for bronchial asthma.